Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Chung Hsing University
With
National Taiwan University Hospital
Primary objective-
• To assess the ability of KEFPEP® to reduce blood pressure.
Secondary objective-
1. To access the effect of KEFPEP® on vascular inflammation or damage.
2. To access the effect of KEFPEP® on cardiovascular diseases prevention.
3. To assess the safety of KEFPEP® .
Age
20–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
1. Male or female patient ages 20 years or older.
2. Belong to either one of the following categories based on the Seventh Report of the Joint National Committee (JNC 7) as measured by office BP at Screening visit:
* Stage I hypertension (SBP 140 - 159 mmHg or DBP 90 - 99 mmHg)
3. Body weight≤90 kg, and BMI≥18.5 kg/m2 or \< 30 kg/m2.
4. NOT on any antihypertensive treatment at the time of entry into the study.
5. Willing to comply with the study procedures and follow-ups.
6. Understand the nature of the study, and have signed informed consent forms.
You may not be if
1. Patients with any of the following conditions within 6 months prior to study participation:
* Secondary hypertension
* Uncontrolled diabetes mellitus
* Renal disease based on the investigator's judgment
* Severe hepatic disease with Child-Pugh class C
* Severe anaemia
* Any malignant disease or serious disease
2. Patients with clinically significant abnormalities in the following laboratory parameters within 2 weeks prior to Screening visit or during the screening period:
